Antu Biotech: Mining and landing in Anhui will have a positive impact, and the proportion of reagent products will increase | Direct performance

① Mr. Feng Chao, financial director of Antu Biotech, said bluntly during the performance meeting that the share of reagent products will increase in the future; ② Chairman Miao Yongjun predicted the growth rate of the molecular, microbiological and other sectors. Among them, there is little new market space in the biochemical sector; ③ Secretary Fang Ruikuan believes that a national collection meeting is likely, and that the mining and landing in Anhui will have a positive impact on the company.

cls.cnMay 20 21:02

Many questions remain unanswered! What is the solution to the problem of subsidiaries being fined frequently under rapid expansion of Kyushu Express regulation? |Go directly to the results meeting

① At the results meeting, Liu Changyun, chairman of Kyushu Express, said that the company will strive to achieve the total number of directly-managed and franchised stores surpassing 25,000 in 2024; ② against the backdrop of rapid growth in the number of stores, the company's revenue growth rate fell to single digits, and even showed a downward trend in performance in the first quarter of this year; ③ the company's subsidiaries have been repeatedly penalized due to issues such as selling poor drugs. How to effectively supervise subsidiaries is a problem that the company needs to solve urgently.

cls.cnMay 17 15:54

Creating a new model for going overseas? Hengrui packaged the GLP-1 product portfolio and reached a major BD deal with a US company

① Tonight, Hengrui Pharmaceutical announced that it reached a BD deal with a special company set up by several capital institutions in the US in May; ② The deal not only involved huge down payments and subsequent milestone payments and sales shares, but also included nearly 20% of the US company's shares; ③ The industry believes that Hengrui Pharmaceutical is joining forces with capital to create a new model for innovative drugs to go overseas, which can achieve a win-win situation for all parties, which is very novel.

cls.cnMay 16 23:18

The actual controller of “Ya Mao” received another warning letter and the financial grant was overdue twice

① Lu Jianming, the actual controller of Ophthalmology Investment and the actual controller of Tongce Medical's participating company, received a warning letter from the Zhejiang Securities Regulatory Bureau; ② Ophthalmology Investment failed to promptly return 112 million yuan of financial aid provided by Tongce Medical from 2019 to August 2020; ③ Ophthalmology Investment and Lu Jianming's actions were recorded in the securities and futures market integrity file.

cls.cnMay 16 19:06

The 40-1 ratio is huge! The new version of the US House of Representatives “Biosafety Act” was passed in a hearing. The industry suggests paying attention to the subsequent run-in between the two house versions of the bill

① At the US House of Representatives hearing, the new version of the “Biosafety Act” was passed with a 40-1 vote; ② Compared with the previous version, the new bill made adjustments in the exemption period for existing contracts/products; at the same time, the companies involved clearly added pharmacological agents; ③ industry experts believe that rapid decoupling is not in the interests of the US industry; next, we need to focus on the run-in between the two houses of law.

cls.cnMay 16 11:15

Passed! Pharmacovigilance waited for an 8-year buffer period, and the company quickly responded

The new version of the US Biosafety Act (H.R. 8333) (hereinafter referred to as the “Act”) has ushered in the latest developments.

Securities TimesMay 16 09:23